FBL10 Antibody

Available Formats and Applications

FBL10 antibodies are commercially available in multiple formats for diverse experimental applications:

Key Suppliers

• Cusabio: Offers unconjugated, HRP-, FITC-, and biotin-conjugated variants .

• Thermo Fisher Scientific: Provides monoclonal antibodies validated for Western blot (WB) and flow cytometry .

Epigenetic Regulation

FBL10 demethylates histone H3K36, influencing heterochromatin formation and gene silencing. This activity links it to cellular differentiation and oncogenesis .

Ubiquitination Pathways

As part of the SCF complex, FBL10 tags substrates like c-Jun for proteasomal degradation. A study (PMID: 17704768) demonstrated its role in suppressing c-Jun-mediated oncogenic signaling .

Clinical Relevance

• Cancer: Dysregulation of FBL10 is associated with tumor progression via aberrant histone modification and protein stability control .

• Autoimmunity: Though not directly studied for FBL10, related F-box proteins are implicated in immune tolerance mechanisms .

Validation Data

• Cusabio’s FBL10 Antibody: Validated for IF, with reactivity confirmed in human samples .

• Thermo Fisher’s MA5-31732: Tested in WB, flow cytometry, and ELISA, with specificity confirmed using recombinant protein .

Limitations and Future Directions

Current research gaps include:

1. In Vivo Functional Studies: Most data derive from in vitro models.

2. Therapeutic Potential: No FBL10-targeted therapies are in clinical trials as of 2025 .

Ongoing studies focus on its role in stem cell maintenance and cancer epigenetics .